首页> 外文期刊>Microbiology >Identification of the chelocardin biosynthetic gene cluster from Amycolatopsis sulphurea: a platform for producing novel tetracycline antibiotics
【24h】

Identification of the chelocardin biosynthetic gene cluster from Amycolatopsis sulphurea: a platform for producing novel tetracycline antibiotics

机译:鉴定来自硫支链霉菌的螯合剂生物合成基因簇:生产新型四环素抗生素的平台

获取原文
           

摘要

Tetracyclines (TCs) are medically important antibiotics from the polyketide family of natural products. Chelocardin (CHD), produced by Amycolatopsis sulphurea, is a broad-spectrum tetracyclic antibiotic with potent bacteriolytic activity against a number of Gram-positive and Gram-negative multi-resistant pathogens. CHD has an unknown mode of action that is different from TCs. It has some structural features that define it as ‘atypical’ and, notably, is active against tetracycline-resistant pathogens. Identification and characterization of the chelocardin biosynthetic gene cluster from A. sulphurea revealed 18 putative open reading frames including a type II polyketide synthase. Compared to typical TCs, the chd cluster contains a number of features that relate to its classification as ‘atypical’: an additional gene for a putative two-component cyclase/aromatase that may be responsible for the different aromatization pattern, a gene for a putative aminotransferase for C-4 with the opposite stereochemistry to TCs and a gene for a putative C-9 methylase that is a unique feature of this biosynthetic cluster within the TCs. Collectively, these enzymes deliver a molecule with different aromatization of ring C that results in an unusual planar structure of the TC backbone. This is a likely contributor to its different mode of action. In addition CHD biosynthesis is primed with acetate, unlike the TCs, which are primed with malonamate, and offers a biosynthetic engineering platform that represents a unique opportunity for efficient generation of novel tetracyclic backbones using combinatorial biosynthesis.
机译:四环素(TCs)是天然产物聚酮化合物家族中的医学上重要的抗生素。硫脲类支原体产生的螯合剂(CHD)是一种广谱四环抗生素,对多种革兰氏阳性和革兰氏阴性多耐药病原体均具有有效的溶菌活性。冠心病的作用方式与TC不同。它具有一些将其定义为“非典型”的结构特征,尤其是对四环素抗性病原体具有活性。鉴定和表征的硫脲曲霉的螯合素生物合成基因簇揭示了18个推定的开放阅读框,包括II型聚酮化合物合酶。与典型的TC相比,chd簇包含许多与其分类为“非典型”的特征:一个可能的双组分环化酶/芳香化酶的附加基因,可能负责不同的芳构化模式,一个可能的基因具有与TC立体化学相反的立体化学的C-4氨基转移酶和一个推定的C-9甲基化酶基因,该基因是TC中这种生物合成簇的独特特征。这些酶共同提供了一个具有不同芳香环C的分子,从而导致TC主链的平面结构异常。这可能是其不同作用方式的原因。另外,与TCs不同,TCD生物合成由乙酸引发,丙二酸则由丙二酸酯引发,为生物合成工程平台提供了独特的机会,可以通过组合生物合成有效地产生新型四环骨架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号